Health
Investigational combo therapy shows promise in treating TP53 mutant MDS and AML patients – News-Medical.Net
Myelodysplastic Syndromes (MDS) and acute myeloid leukemia (AML) are rare hematologic malignancies of the bone marrow.
Myelodysplastic Syndromes (MDS) and acute myeloid leukemia (AML) are rare hematologic malignancies of the bone marrow. They can occur spontaneously or secondary to treatment for other cancers, so called therapy related disease, which is frequently associated with a mutation of the tumor suppressor gene TP53. Standard treatment for these patients includes hypomethylating agents such as azacitidine or decitabine but unfortunately outcomes are very poor.
Patients with TP53-mutant disease, which is…
-
General19 hours agoVictorian school teacher charged with soliciting child abuse material
-
General10 hours agoAustralia loses ODI series to South Africa with defeat in second game in Mackay
-
Business22 hours agoEconomic roundtable or maturity test?
-
Noosa News14 hours agoPalestine protesters forced into last-minute reroute